Type of security: Stock
Sector: Health Care
Industry: Precision Instruments
The data is delayed by 15 minutes.
Description: NeoGenomics, Inc., together with its subsidiary, NeoGenomics Laboratories, Inc., operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company performs analyses for hematopoietic cancers, such as leukemia and lymphoma; and solid tumor cancers comprising breast, lung, colon, and bladder cancer. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry testing services to identify cell proteins in a tissue section; and molecular testing services that focus on the analysis of DNA and RNA, as well as on t
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||11.4%||Sales Growth - Q/Q||-7.89%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||0.33%||ROE||0.45%||ROI|
|Current Ratio||4.14||Quick Ratio||3.95||Long Term Debt/Equity||0.15||Debt Ratio||0.23|
|Gross Margin||45.2%||Operating Margin||1.37%||Net Profit Margin||0.29%||Dividend Payout Ratio|
|Cash From Financing Activities||-1.45 M||Cash From Investing Activities||-1.18 M||Cash From Operating Activities||1.9 M||Gross Profit||10.81 M|
|Net Profit||-180 K||Operating Profit||30 K||Total Assets||82.97 M||Total Current Assets||59.6 M|
|Total Current Liabilities||15.12 M||Total Debt||10.05 M||Total Liabilities||22.1 M||Total Revenue||24.37 M|
|High 52 week||18.5||Low 52 week||7.23||Last close||15.3||Last change||0.46%|
|RSI||83.07||Average true range||0.64||Beta||0.33||Volume||150.71 K|
|Simple moving average 20 days||16.73%||Simple moving average 50 days||3.81%||Simple moving average 200 days||15.02%|
|Performance Week||2.2%||Performance Month||15.47%||Performance Quart||13.42%||Performance Half||9.6%|
|Performance Year||91.97%||Performance Year-to-date||21.33%||Volatility daily||3.93%||Volatility weekly||8.8%|
|Volatility monthly||18.02%||Volatility yearly||62.44%||Relative Volume||210.71%||Average Volume||1.45 M|
|New High||New Low|
2019-03-12 10:27:28 | See what the IHS Markit Score report has to say about Neogenomics Inc.
2019-03-11 12:59:00 | Here's Why Genetic Testing Stocks Rose as Much as 42.9% in February
2019-03-07 16:50:00 | NeoGenomics To Present At 39th Annual Cowen and Company Health Care Conference
2019-03-05 08:06:29 | See what the IHS Markit Score report has to say about Neogenomics Inc.
2019-02-23 19:09:29 | Back Above $4k: Bitcoin’s Price Jumps to a Two-Month High
2019-02-20 00:40:04 | Edited Transcript of NEO earnings conference call or presentation 19-Feb-19 1:30pm GMT
2019-02-19 14:22:50 | Neogenomics Inc NEO Q4 2018 Earnings Conference Call Transcript
2019-02-19 07:32:41 | NeoGenomics: 4Q Earnings Snapshot
2019-02-19 06:30:00 | NeoGenomics, Inc. to Host Earnings Call
2019-02-12 15:00:12 | Is NeoGenomics, Inc. NASDAQ:NEO Excessively Paying Its CEO?
2019-02-12 10:30:03 | NeoGenomics NEO Reports Next Week: What to Know Ahead of the Release
2019-02-12 08:19:01 | 5 Breakout Stocks for Stellar Returns
2019-02-08 22:33:00 | Here's Why Genetic Testing Stocks Rose as Much as 31.8% in January
2019-02-08 08:03:12 | See what the IHS Markit Score report has to say about Neogenomics Inc.
2019-01-29 13:10:00 | NeoGenomics Is Poised For Further Gains - Go Long on a Shallow Dip
2019-01-29 09:30:02 | Is NeoGenomics NEO Outperforming Other Medical Stocks This Year?
2019-01-24 08:07:01 | See what the IHS Markit Score report has to say about Neogenomics Inc.
2019-01-22 19:11:00 | 3 Top Growth Stocks to Buy Right Now
2019-01-18 07:40:00 | Report: Developing Opportunities within Macerich, Illinois Tool Works, NeoGenomics, Bunge, Dolby Laboratories, and Cracker Barrel Old Country Store — Future Expectations, Projections Moving into 2019
2019-01-17 08:03:41 | See what the IHS Markit Score report has to say about Neogenomics Inc.
2019-01-15 08:03:27 | See what the IHS Markit Score report has to say about Neogenomics Inc.
2019-01-09 12:41:00 | Here's Why NeoGenomics Rocketed Higher Today
2019-01-09 08:02:48 | See what the IHS Markit Score report has to say about Neogenomics Inc.
2019-01-08 17:58:00 | NeoGenomics Set to Join S&P SmallCap 600
2018-12-25 09:30:02 | Is NeoGenomics NEO Stock Outpacing Its Medical Peers This Year?
2018-12-21 17:45:10 | NeoGenomics NEO Stock Moves -1.04%: What You Should Know
2018-12-20 08:03:58 | See what the IHS Markit Score report has to say about Neogenomics Inc.
2018-12-19 00:45:45 | NeoGenomics, Inc. NEO: Hedge Funds Are Snapping Up
2018-12-17 10:10:00 | GE Sells Last of Its NeoGenomics Stock for $130 Million
2018-12-13 10:32:03 | 5 Healthcare Bets to Stay in Investors Good Books Next Year
2018-12-13 07:00:00 | NeoGenomics Appoints Dr. Lawrence M. Weiss as Chief Scientific Officer
2018-12-11 16:10:00 | NeoGenomics Announces Secondary Offering of Common Stock by Selling Stockholder
2018-12-10 09:10:00 | NeoGenomics Completes Acquisition of Genoptix, Inc.
2018-12-06 09:30:02 | Is NeoGenomics NEO Outperforming Other Medical Stocks This Year?
2018-12-03 09:33:02 | QIAGEN QGEN Partners NeoGenomics to Widen CDx Tests Reach
2018-11-27 10:44:03 | Eyenovia Initiates Phase III Study for Mydriasis Candidate
2018-11-12 15:00:12 | What Kind Of Investor Owns Most Of NeoGenomics Inc NASDAQ:NEO?
2018-11-12 07:35:00 | Research Report Identifies Ironwood Pharmaceuticals, The AES, Accuray, Ball, Park Hotels & Resorts, and NeoGenomics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
2018-10-30 15:33:30 | Dow Jones Leads Fragile Rebound; Will This Sector Head A Recovery?
2018-10-30 14:04:38 | Edited Transcript of NEO earnings conference call or presentation 30-Oct-18 12:30pm GMT
2018-10-30 08:35:12 | NeoGenomics NEO Q3 Earnings and Revenues Top Estimates
2018-10-30 07:31:55 | NeoGenomics: 3Q Earnings Snapshot
2018-10-30 07:00:00 | NeoGenomics Reports 17% Revenue Growth to Record $69 Million